AKT1 and breast cancer: Silencing of miR-126 in a murine breast cancer model caused reduced induction and suppressive function of CD4+ FOXP3+ regulatory T cells (Tregs) through the PI3K/Akt pathway, and also endowed antitumour effects of CD8+ T cells [121].